Phase IIIa Clinical Trial of Oral Semaglutide Completed
Novo Nordisk has announced it has completed the second Phase IIIa trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilises Emisphere Technologies’ proprietary Eligen® Technology.
Emisphere is a drug delivery company that utilises its proprietary Eligen® Technology to develop new oral formulations of therapeutic agents. Emisphere partners with global pharmaceutical companies for the development of new orally delivered therapeutics.
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...
Make an enquiry
Thank you for submitting the form. Your enquiry will be submitted to the company.